Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cedar Pollen Allergy - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Cedar Pollen Allergy - Pipeline Review, H1 2016', provides an overview of the Cedar Pollen Allergy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews pipeline therapeutics for Cedar Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cedar Pollen Allergy therapeutics and enlists all their major and minor projects - The report assesses Cedar Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cedar Pollen Allergy Overview 6 Therapeutics Development 7 Pipeline Products for Cedar Pollen Allergy - Overview 7 Pipeline Products for Cedar Pollen Allergy - Comparative Analysis 8 Cedar Pollen Allergy - Therapeutics under Development by Companies 9 Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 10 Cedar Pollen Allergy - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Cedar Pollen Allergy - Products under Development by Companies 14 Cedar Pollen Allergy - Products under Investigation by Universities/Institutes 15 Cedar Pollen Allergy - Companies Involved in Therapeutics Development 16 ALK-Abello A/S 16 Anergis SA 17 Circassia Pharmaceuticals Plc 18 Immunomic Therapeutics, Inc. 19 Japan Tobacco Inc. 20 REGiMMUNE Corporation 21 Cedar Pollen Allergy - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Combination Products 23 Assessment by Target 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 AllerJ - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ASP-4070 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Drugs for Cedar Pollen Allergy - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 JCC-LAMP-Vax - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 MC-LAMP-Vax - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 RGI-1001 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 TO-206 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Vaccine for Cedar Pollen Allergy - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vaccine for Japanese Cedar Pollen Allergy - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Cedar Pollen Allergy - Recent Pipeline Updates 42 Cedar Pollen Allergy - Dormant Projects 47 Cedar Pollen Allergy - Product Development Milestones 48 Featured News & Press Releases 48 Aug 07, 2015: ALK's partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet 48 Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 48 Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 48 Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy 49 Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for Cedar Pollen Allergy, H1 2016 7 Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Cedar Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2016 16 Cedar Pollen Allergy - Pipeline by Anergis SA, H1 2016 17 Cedar Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 18 Cedar Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2016 19 Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc., H1 2016 20 Cedar Pollen Allergy - Pipeline by REGiMMUNE Corporation, H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Assessment by Combination Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Cedar Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2016 42 Cedar Pollen Allergy - Dormant Projects, H1 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
